138 related articles for article (PubMed ID: 25125683)
1. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.
Vail ME; Murone C; Tan A; Hii L; Abebe D; Janes PW; Lee FT; Baer M; Palath V; Bebbington C; Yarranton G; Llerena C; Garic S; Abramson D; Cartwright G; Scott AM; Lackmann M
Cancer Res; 2014 Aug; 74(16):4470-81. PubMed ID: 25125683
[TBL] [Abstract][Full Text] [Related]
2. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents.
Vearing C; Lee FT; Wimmer-Kleikamp S; Spirkoska V; To C; Stylianou C; Spanevello M; Brechbiel M; Boyd AW; Scott AM; Lackmann M
Cancer Res; 2005 Aug; 65(15):6745-54. PubMed ID: 16061656
[TBL] [Abstract][Full Text] [Related]
3. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
La Rocca F; Airoldi I; Di Carlo E; Marotta P; Falco G; Simeon V; Laurenzana I; Trino S; De Luca L; Todoerti K; Villani O; Lackmann M; D'Auria F; Frassoni F; Neri A; Del Vecchio L; Musto P; Cilloni D; Caivano A
Cell Oncol (Dordr); 2017 Oct; 40(5):483-496. PubMed ID: 28721629
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth.
To C; Farnsworth RH; Vail ME; Chheang C; Gargett CE; Murone C; Llerena C; Major AT; Scott AM; Janes PW; Lackmann M
PLoS One; 2014; 9(11):e112106. PubMed ID: 25420155
[TBL] [Abstract][Full Text] [Related]
5. EphA3 contributes to tumor growth and angiogenesis in human gastric cancer cells.
Lv XY; Wang J; Huang F; Wang P; Zhou JG; Wei B; Li SH
Oncol Rep; 2018 Oct; 40(4):2408-2416. PubMed ID: 30066881
[TBL] [Abstract][Full Text] [Related]
6. EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
Charmsaz S; Al-Ejeh F; Yeadon TM; Miller KJ; Smith FM; Stringer BW; Moore AS; Lee FT; Cooper LT; Stylianou C; Yarranton GT; Woronicz J; Scott AM; Lackmann M; Boyd AW
Leukemia; 2017 Aug; 31(8):1779-1787. PubMed ID: 27922598
[TBL] [Abstract][Full Text] [Related]
7. Effects of cancer-associated EPHA3 mutations on lung cancer.
Zhuang G; Song W; Amato K; Hwang Y; Lee K; Boothby M; Ye F; Guo Y; Shyr Y; Lin L; Carbone DP; Brantley-Sieders DM; Chen J
J Natl Cancer Inst; 2012 Aug; 104(15):1182-97. PubMed ID: 22829656
[TBL] [Abstract][Full Text] [Related]
8. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.
Day BW; Stringer BW; Al-Ejeh F; Ting MJ; Wilson J; Ensbey KS; Jamieson PR; Bruce ZC; Lim YC; Offenhäuser C; Charmsaz S; Cooper LT; Ellacott JK; Harding A; Leveque L; Inglis P; Allan S; Walker DG; Lackmann M; Osborne G; Khanna KK; Reynolds BA; Lickliter JD; Boyd AW
Cancer Cell; 2013 Feb; 23(2):238-48. PubMed ID: 23410976
[TBL] [Abstract][Full Text] [Related]
9. The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis.
Lahtela J; Pradhan B; Närhi K; Hemmes A; Särkioja M; Kovanen PE; Brown A; Verschuren EW
Dis Model Mech; 2015 Apr; 8(4):393-401. PubMed ID: 25713296
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.
Andretta E; Cartón-García F; Martínez-Barriocanal Á; de Marcondes PG; Jimenez-Flores LM; Macaya I; Bazzocco S; Bilic J; Rodrigues P; Nieto R; Landolfi S; Ramon Y Cajal S; Schwartz S; Brown A; Dopeso H; Arango D
Sci Rep; 2017 Feb; 7():41576. PubMed ID: 28169277
[TBL] [Abstract][Full Text] [Related]
11. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration.
Clifford N; Smith LM; Powell J; Gattenlöhner S; Marx A; O'Connor R
J Cell Biochem; 2008 Dec; 105(5):1250-9. PubMed ID: 18814179
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
[TBL] [Abstract][Full Text] [Related]
13. Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics.
London M; Gallo E
Mol Biol Rep; 2020 Jul; 47(7):5523-5533. PubMed ID: 32621117
[TBL] [Abstract][Full Text] [Related]
14. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.
Lisabeth EM; Fernandez C; Pasquale EB
Biochemistry; 2012 Feb; 51(7):1464-75. PubMed ID: 22242939
[TBL] [Abstract][Full Text] [Related]
15. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
16. A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3.
Lahtela J; Corson LB; Hemmes A; Brauer MJ; Koopal S; Lee J; Hunsaker TL; Jackson PK; Verschuren EW
Cell Cycle; 2013 Feb; 12(4):625-34. PubMed ID: 23324396
[TBL] [Abstract][Full Text] [Related]
17. A critical role for the EphA3 receptor tyrosine kinase in heart development.
Stephen LJ; Fawkes AL; Verhoeve A; Lemke G; Brown A
Dev Biol; 2007 Feb; 302(1):66-79. PubMed ID: 17046737
[TBL] [Abstract][Full Text] [Related]
18. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
19. EPHA3 as a novel therapeutic target in the hematological malignancies.
Keane N; Freeman C; Swords R; Giles FJ
Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
[TBL] [Abstract][Full Text] [Related]
20. Unliganded EphA3 dimerization promoted by the SAM domain.
Singh DR; Cao Q; King C; Salotto M; Ahmed F; Zhou XY; Pasquale EB; Hristova K
Biochem J; 2015 Oct; 471(1):101-9. PubMed ID: 26232493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
